

Determining the use of smart watches to detect irregular heart rhythms for people following a stroke

| | | |
|--|---|---|
| Submission date 10/01/2022 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol |
| Registration date 13/01/2022 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results |
| Last Edited 18/12/2025 | Condition category Circulatory System | <input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

Atrial fibrillation is a common irregular heart rhythm. Atrial fibrillation increases a person's risk of stroke, but often remains undetected. In previous studies, smart watches have been shown to work well for detecting atrial fibrillation in the general population. The use of smart watches to identify atrial fibrillation in people following a stroke has not yet been explored. Identifying atrial fibrillation for patients following a stroke means appropriate treatment can be started to reduce the person's risk of having another stroke. The aim of the current study is to determine how well Huawei smart watches can identify atrial fibrillation in patient's following a stroke.

Who can participate?

All adults at participating hospitals who have had an ischaemic stroke (where the stroke is caused by loss of blood flow to the brain) confirmed by a stroke doctor, unless they are unable to provide consent to take part or they are receiving end-of-life care.

What does the study involve?

At the time of stroke, patients have a lot of information collected about their health, we will copy information from a patient's medical records about their health. We will also ask the patients to complete some additional questionnaires including about their health and well-being. We will ask the patients to wear a smart band for four weeks. The smart band will be linked to a mobile phone application. If the person has a phone which works with the band, we will ask them to download the application to their own phone. If the person does not have a compatible phone, the person will be provided with a phone which will be asked to return at the end of the study period. The smart band will track their heart rhythm and if atrial fibrillation is suspected, the person will be invited to attend a hospital appointment. At the hospital appointment, further tests will be conducted, such as an electrocardiogram (ECG), to determine if the person does have atrial fibrillation. We will ask the patients 6 and 12-months later to repeat the questionnaires.

What are the possible benefits and risks of participating?

Some of the questionnaires will ask questions about the individual's health. It is possible that

some people might find some of the questions in the assessments upsetting. Participants do not need to answer any questions they would not like to. If the participant has any distress the data collection will be paused to provide time for the individual to consider whether to continue or withdraw from the study. If any medical risk is discovered such as a previously unidentified medical condition, then the information collected may be referred to an appropriate medical practitioner at the hospital for further examination. However, participation in the study is not a substitute for a 'health check'. The smart band has been designed to be worn continuously, but if the participant finds the smart band uncomfortable at any time it can be removed.

Where is the study run from?
Liverpool University (UK)

When is the study starting and how long is it expected to run for?
February 2020 to Deember 2025

Who is funding the study?
National Institute for Health Research (NIHR) (UK).
Huawei Technologies Co. Ltd. (China)

Who is the main contact?
Dr Stephanie Harrison,
Prof Gregory Lip,
huaweistrokestudy@liverpool.ac.uk

Contact information

Type(s)
Scientific

Contact name
Dr Stephanie Harrison

Contact details
William Henry Duncan Building
6 West Derby Street
University of Liverpool
Liverpool
United Kingdom
L7 8TX
-
huaweistrokestudy@liverpool.ac.uk

Type(s)
Principal investigator

Contact name
Prof Gregory Lip

Contact details
Liverpool Centre for Cardiovascular Science
William Henry Duncan building

6 West Derby Street
Liverpool
United Kingdom
L7 8TX
-
huaweistrokestudy@liverpool.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)
302919

ClinicalTrials.gov (NCT)
Nil known

Central Portfolio Management System (CPMS)
50451

National Institute for Health and Care Research (NIHR)
201320

Study information

Scientific Title
Evaluation of Huawei smartwear for detection of atrial fibrillation in a post-stroke population: the Huawei stroke study

Study objectives
Is a smart band useful to detect atrial fibrillation in patients following a stroke?
How is it of relevance and importance to patients and public?

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved 23/11/2021, East Midlands - Nottingham 2 Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, UK; +44 203 443 6294; nottingham2.rec@hra.nhs.uk), ref: 21/EM/0214

Study design
Interventional non-randomized

Primary study design
Interventional

Study type(s)
Diagnostic

Health condition(s) or problem(s) studied

Detection of atrial fibrillation in patients who have experienced a stroke

Interventions

We are planning this study for people who have recently had a confirmed ischaemic stroke. We will ask people to take part in the study before they leave hospital following their stroke. We will collect information about people's health following their stroke. At the time of a stroke, a lot of information is already collected about the person who has experienced a stroke, so we plan to collect this information in the study from electronic medical records. There are some questions which are needed for the study which are not already being collected in hospitals for people following

a stroke about their wellbeing, quality of life and fatigue. So, we will ask the people involved in the study to answer additional questionnaires about these topics.

We will ask the participants to wear a Huawei smart band for four weeks which will be linked to a smart phone application (app). Prior to participant recruitment, a site initiation visit will be conducted at each site to provide training to the research nurses including training to use the smart band and app, so they can in turn train the recruited patients and/or their family members to use the smart band and app. We have discussed the study design with two people with experience of stroke. Following advice from these individuals, we will provide participants with an easy-to-follow print out of how to use the technology and a phone number to call with an issues using the technology. After the fourweek period, participants who have borrowed a phone will be asked to return it. For participants who are using their own smart phone for the study, they will be able to continue to use the smart band and provide data for the study for up to six months.

A research nurse will determine people who are eligible for the study and ask them if they would like to take part. We are aiming to have 1000 people take part in the study. This has been determined by calculating how many people would be needed to be sufficient for the intended analysis and answer the research question. We will produce an interim report once we have recruited all of the people to the study.

At six and twelve months after the person is admitted to hospital for a stroke and takes part in the study, we will contact them again and ask them to complete the same questionnaires about their health to see how their health has changed one-year post-stroke. We will do this by posting some questionnaires and asking some questions over the telephone or by video call wherever possible. Alternatively, the person can complete these questionnaires at the end of an outpatient appointment. If this is not possible, the person will be invited to attend an appointment at the hospital where they were initially recruited for the study. We will also ask people if we can access their hospital records following their stroke to determine what hospital visits they have had.

We have discussed the study plans with two people with experience of stroke. They gave valuable input to the study plans including advising on training documents for the use of the Huawei smart band.

Intervention Type

Other

Primary outcome(s)

Detection of atrial fibrillation by the Huawei smart band measured continuously up to week 4

Key secondary outcome(s)

Patient outcomes:

1. Performance in activities of daily living measured using the Barthel Index at baseline, 6 months and 12 months.
2. General health measured using the Patient Health Questionnaire (PHQ)-9 at baseline, 6 months and 12 months.
3. Anxiety measured using the General Anxiety Disorder (GAD)-7 at baseline, 6 months and 12 months.
4. Obstructive Sleep Apnea measured using the STOP BANG questionnaire at baseline, 6 months and 12 months.
5. Health related quality of life measured using the EQ-5D-5L at baseline, 6 months and 12 months.
6. Modified European Heart Rhythm Association (mEHRA) symptom score measured at baseline, 6 months and 12 months.
7. Treatment burden questionnaire measured at baseline, 6 months and 12 months.
8. Montreal Cognitive Assessment (MoCA) measured at baseline and 12 months.
9. Participant 'intervention acceptability' survey measured at one-month.
10. Participant interviews, conducted with a sub-sample of patients to explore intervention acceptability at one-month.

Outcomes measured in staff involved in training participants to use the smart bands:

11. Staff interviews to explore challenges in delivery of the training to participants to use the smart bands, time taken (to deliver the intervention and ongoing support with the system provided to the patient), unexpected benefits and/or consequences, and recommendations for improvement at six months.
12. Staff 'intervention acceptability' survey measured at baseline.

Completion date

31/12/2025

Eligibility

Key inclusion criteria

1. ≥ 18 years old
2. Current in-patient at the time of baseline data collection for recent ischaemic stroke; confirmed by stroke physician and/or imaging (computerized tomography (CT) or magnetic resonance imaging (MRI))

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

199 years

Sex

All

Total final enrolment

491

Key exclusion criteria

1. Inability to provide informed consent
2. Receiving palliative or end-of-life care

Date of first enrolment

14/03/2022

Date of final enrolment

30/06/2024

Locations

Countries of recruitment

United Kingdom

Study participating centre

The Royal Liverpool University Hospital

Prescot Street

Liverpool

England

L7 8XP

Study participating centre

Whiston Hospital

Warrington Road

Prescot

England

L35 5DR

Study participating centre

Arrowe Park Hospital

Arrowe Park Road

Wirral

England

CH49 5PE

Sponsor information

Organisation

University of Liverpool

ROR

<https://ror.org/04xs57h96>

Funder(s)

Funder type

Government

Funder Name

NIHR Central Commissioning Facility (CCF)

Funder Name

National Institute for Health Research (NIHR) (UK)

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Funder Name

Huawei Technologies

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

China

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| Protocol article | Participant information sheet | 06/12/2022 | 12/12/2022 | Yes | No |
| HRA research summary | | | 26/07/2023 | No | No |
| Participant information sheet | | 11/11/2025 | 11/11/2025 | No | Yes |
| Protocol file | version 4.0 | 22/10/2021 | 13/01/2022 | No | No |